An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs PCS 499 (Primary)
- Indications Necrobiosis lipoidica
- Focus Adverse reactions
- Sponsors Processa Pharmaceuticals
- 26 Aug 2019 Planned End Date changed from 1 Mar 2021 to 1 Aug 2020.
- 26 Aug 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2020.
- 26 Aug 2019 Status changed from recruiting to active, no longer recruiting.